These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12691636)

  • 1. Matrix metalloproteinase in left ventricular remodeling and heart failure.
    Shastry S; Hayden MR; Lucchesi PA; Tyagi SC
    Curr Cardiol Rep; 2003 May; 5(3):200-4. PubMed ID: 12691636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlling myocardial matrix remodeling: implications for heart failure.
    Rao VU; Spinale FG
    Cardiol Rev; 1999; 7(3):136-43. PubMed ID: 10423664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethanol extract from Epimedium brevicornum attenuates left ventricular dysfunction and cardiac remodeling through down-regulating matrix metalloproteinase-2 and -9 activity and myocardial apoptosis in rats with congestive heart failure.
    Song YH; Li BS; Chen XM; Cai H
    Int J Mol Med; 2008 Jan; 21(1):117-24. PubMed ID: 18097624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
    Yang YJ; Zhang X; Zhu WL; Huang Y
    Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer.
    Cox MJ; Hawkins UA; Hoit BD; Tyagi SC
    Circulation; 2004 May; 109(17):2123-8. PubMed ID: 15117845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tumor necrosis factor alpha and myocardial matrix metalloproteinases in left ventricular remodeling].
    Wang XM; Yang LX; Zhu SJ; Yang YJ; Guo CM; Qi F; Wei L; Shi YK; Wang Y; Ren L
    Zhonghua Nei Ke Za Zhi; 2004 Nov; 43(11):828-31. PubMed ID: 15634542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of nitric oxide in matrix remodeling in diabetes and heart failure.
    Tyagi SC; Hayden MR
    Heart Fail Rev; 2003 Jan; 8(1):23-8. PubMed ID: 12652156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MMP induction and inhibition in myocardial infarction.
    Lindsey ML
    Heart Fail Rev; 2004 Jan; 9(1):7-19. PubMed ID: 14739764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.
    Kandalam V; Basu R; Moore L; Fan D; Wang X; Jaworski DM; Oudit GY; Kassiri Z
    Circulation; 2011 Nov; 124(19):2094-105. PubMed ID: 21986284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metallopropteinases in heart failure.
    Tousoulis D; Kampoli AM; Papageorgiou N; Antoniades C; Siasos G; Latsios G; Tsiamis E; Stefanadis C
    Curr Top Med Chem; 2012; 12(10):1181-91. PubMed ID: 22519448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel approaches to retard ventricular remodeling in heart failure.
    Spinale FG
    Eur J Heart Fail; 1999 Mar; 1(1):17-23. PubMed ID: 10937974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
    Spinale FG
    Circ Res; 2002 Mar; 90(5):520-30. PubMed ID: 11909815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metalloproteinase in myocardial adaptation and maladaptation.
    Tyagi SC; Hoit BD
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):241-6. PubMed ID: 12490970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis.
    López B; González A; Díez J
    Curr Opin Nephrol Hypertens; 2004 Mar; 13(2):197-204. PubMed ID: 15202614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pentaerythritol Tetranitrate Targeting Myocardial Reactive Oxygen Species Production Improves Left Ventricular Remodeling and Function in Rats With Ischemic Heart Failure.
    Fraccarollo D; Galuppo P; Neuser J; Bauersachs J; Widder JD
    Hypertension; 2015 Nov; 66(5):978-87. PubMed ID: 26351025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinases: pathways of induction by bioactive molecules.
    Tsuruda T; Costello-Boerrigter LC; Burnett JC
    Heart Fail Rev; 2004 Jan; 9(1):53-61. PubMed ID: 14739768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation.
    Mukherjee R; Herron AR; Lowry AS; Stroud RE; Stroud MR; Wharton JM; Ikonomidis JS; Crumbley AJ; Spinale FG; Gold MR
    Am J Cardiol; 2006 Feb; 97(4):532-7. PubMed ID: 16461051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation.
    Nishikawa N; Yamamoto K; Sakata Y; Mano T; Yoshida J; Miwa T; Takeda H; Hori M; Masuyama T
    Cardiovasc Res; 2003 Mar; 57(3):766-74. PubMed ID: 12618238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs.
    Yarbrough WM; Mukherjee R; Brinsa TA; Dowdy KB; Scott AA; Escobar GP; Joffs C; Lucas DG; Crawford FA; Spinale FG
    J Thorac Cardiovasc Surg; 2003 Mar; 125(3):602-10. PubMed ID: 12658202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine-dependent cardiac remodeling and endothelial-myocyte coupling in a 2 kidney, 1 clip Goldblatt hypertension mouse model.
    Tyagi N; Moshal KS; Lominadze D; Ovechkin AV; Tyagi SC
    Can J Physiol Pharmacol; 2005 Jul; 83(7):583-94. PubMed ID: 16091784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.